Barasertib — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	1	1	12	—	—	2005-05
Leukemia	Phase3	Phase 3	0	1	6	—	—	2006-05
Malignant Lung Neoplasm	Phase2	Phase 2	1	0	2	—	—	Dec 1, 2017

Computedclinicaltrials

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
AURKB Overexpression1
Alisertib + Barasertib

Clinical trials

Trials with this intervention (12)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–12 of 12 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04745689	Study of AZD2811 + Durvalumab in ES-SCLC(TAZMAN)	active not recruiting	Phase 2	31	AstraZenecaINDUSTRY	4	Jul 6, 2026	clinicaltrials
NCT03217838	Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.	terminated